Tesamorelin

Tesamorelin is worth knowing about because it is the answer to a question people often ask: is there an approved peptide that actually reduces belly fat. There is, and this is it.

It works by copying growth hormone releasing hormone, so instead of injecting growth hormone directly, it prompts the pituitary gland to release its own in a more natural rhythm.

Why people are talking about it#

Because it targets the fat that matters. Visceral fat is the fat packed around the organs, and it is the kind most strongly linked to metabolic disease. Being able to reduce it specifically, rather than hoping it goes along with general weight loss, is genuinely useful.

The other reason is that it has an approval. A regulator reviewed the full dataset and agreed the drug does what its label says, which puts it in a different category from almost everything else in this section.

What people take it for#

Its licence is specific: excess visceral fat in people with HIV-associated lipodystrophy, where fat redistributes in ways that are both uncomfortable and metabolically harmful. In that group it works.

It is also prescribed off-label for deep abdominal fat in people without HIV, and has been studied for fatty liver disease.

Visceral fat#

The claim is a measurable reduction in the fat packed around the organs. The mechanism is a growth hormone pulse acting through IGF-1, and visceral fat is unusually responsive to growth hormone signalling compared with fat under the skin.

This was measured on CT scans in the registration trials, over 26 to 52 weeks.

Fatty liver#

The claim is less fat stored in the liver, on the same growth hormone axis, and liver fat tends to move with visceral fat.

Trials in people with HIV and fatty liver have reported reductions in liver fat measured by imaging. That population is specific, and the result has not been established in the much larger group with metabolic fatty liver disease.

Off-label use for ordinary belly fat#

The claim made in clinics is that the same effect applies to anyone carrying deep abdominal fat, and the mechanism does not obviously care whether someone has HIV.

The evidence does not follow automatically, though: a drug tested in a population with a particular pattern of fat redistribution has not been tested in the general one. That use sits on thinner ground than the licensed one.

What the evidence shows#

The registration trials showed meaningful reductions in visceral fat, measured on CT rather than by tape measure, over 26 to 52 weeks. It is approved by the US Food and Drug Administration.

Two limits are worth stating plainly. The fat returns when the drug stops, which makes it an ongoing treatment rather than a course. And the trials measured fat, not the hard outcomes that fat predicts, so nobody has shown that taking tesamorelin prevents a heart attack.

The side effects reflect what growth hormone does. Fluid retention causes joint aches and sometimes carpal tunnel symptoms, and injection site reactions are common. Muscle pain, pins and needles in the hands and swelling in the legs appear in the trial data above placebo rates.

How it is taken#

The licensed product is a daily subcutaneous injection into the abdomen, prescribed and monitored, with IGF-1 checked during treatment. It is one of the more expensive options in this area, and off-label use is generally not covered by insurance or public health systems.

How it compares#

Against the GLP-1 drugs#

Semaglutide and tirzepatide reduce total body weight substantially through appetite. Tesamorelin reduces visceral fat specifically, without much effect on overall weight, which makes them different tools rather than competitors.

Against sermorelin#

Sermorelin works on the same axis and is compounded rather than licensed. Tesamorelin has completed registration trials and an approval behind it, which is the practical difference.

Common questions#

Does it work for ordinary belly fat?

The trials were run in people with HIV-associated lipodystrophy. Off-label use in others is common and much less well studied.

Does the fat come back?

Yes, when treatment stops. The effect depends on continued use.

Why does it target visceral fat specifically?

Visceral fat is more responsive to growth hormone signalling than fat under the skin, so the same pulse moves it further.

Is it expensive?

Yes, and off-label use is generally paid for privately.